First HCFA Coverage Panel To Review Stem Cell Transplantation
This article was originally published in The Gray Sheet
Executive Summary
High dose chemotherapy and stem cell transplantation combination treatment for multiple myeloma will be reviewed Sept. 15-16 by the Health Care Financing Administration Medicare Coverage Advisory Committee's drugs, biologics and therapeutics panel, an Aug. 13 Federal Register notice states.